Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD

NCT02884544 is registered in ClinicalTrials.gov with Ironshore Pharmaceuticals and Development, Inc as lead sponsor.

NCT NCT02884544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02884544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2016
Completion date
December 27, 2016
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit hyperactivity disorder (adhd)